How Do I Know My GLP-1 Is Working?

How do you know your GLP-1 is working? The clearest early signs are that your appetite drops and your "food noise" quiets, followed over weeks by a downward weight trend and a shrinking waist. What does not tell you it is working is how many side effects you have. Effectiveness shows up in appetite, the weight trend, and body composition, not in nausea.

This article covers Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). It is general education, not medical advice, and includes no dosing guidance. If you are worried the drug is not helping, the answer is to check the right signals, then talk to your prescriber.

The first real sign: quieter appetite and "food noise"

The earliest and most reliable signal is not on the scale. It is in your head. Many people notice within the first days to weeks that they feel full faster, think about food less, and stop grazing.

"Food noise" is the colloquial term for the persistent, intrusive preoccupation with food, the cravings and mental chatter about what and when to eat that runs even when you are not physically hungry. GLP-1 receptors sit in the brain's reward circuits, and the medication appears to dampen the dopamine response to food cues, which is why so many users describe the noise simply going quiet. That quieting is one of the more dependable subjective signs the drug is active. We dig into it in "food noise" on a GLP-1.

If appetite and food noise have eased, the drug is doing its core job, even if the scale has not caught up yet.

The weight trend, read correctly

Weight is a real signal, but only as a trend. A single day's reading is almost useless because body weight swings daily from water, sodium, glycogen, hormones, and digestion.

Look at your weekly average over several weeks, not individual mornings. Weight loss also tends to be fastest in the first roughly 16 to 20 weeks and then decelerates, which is normal, not the drug quitting. And because weekly GLP-1 drugs take about four to five weeks to reach steady state, early progress can feel uneven before it settles.

A flat week, or even a flat two or three weeks, is not failure. A genuinely flat trend over many weeks, with appetite suppression clearly gone, is the threshold for a prescriber conversation. We cover the full picture in why your GLP-1 weight loss stalled.

Why side effects are not the scoreboard

A stubborn myth says rough side effects mean the drug is "really working." It is not true. Side effects come from the gastric-slowing mechanism, which also drives satiety, so they often appear together, but their intensity does not predict how much weight you will lose.

Some people lose substantial weight with minimal nausea. Others feel awful early and lose at an ordinary pace. Treating side effects as a progress meter leads to bad decisions, like tolerating misery you do not need to. Track side effects to manage your tolerance and inform your prescriber, not to judge effectiveness; see tracking GLP-1 side effects.

The metric that confirms it: body composition

Here is the trap. The scale going down feels like success, but it cannot tell you whether you are losing fat or muscle. Research suggests roughly 25 to 40% of weight lost on GLP-1 medications can come from lean mass, which includes muscle, water, and organ mass, not solely skeletal muscle.

So "working" should mean more than a smaller number. It should mean losing mostly fat while holding your muscle. The only way to confirm that is to look at body composition, not weight alone, whether through a DEXA scan, a smart scale tracked for trend, tape measurements, or strength benchmarks. We compare the methods in body composition tracking on a GLP-1 and explain the fat-versus-muscle question in fat loss vs muscle loss on a GLP-1.

A GLP-1 that is dropping fat while your strength holds is unambiguously working. A GLP-1 that is dropping the scale while your strength falls is working against your long-term goals.

When "not working" is really the plan around it

Sometimes the drug is doing its part and the disappointment is elsewhere. Appetite suppression eases the deficit, but it does not feed you protein or lift weights for you.

If you are losing the scale but feel soft, weak, and tired, the medication may be working while your protein and training are not, which lets too much of the loss come from muscle. That is fixable without changing the drug: hit your protein target (commonly cited around 1.2 to 1.6 g/kg of body weight per day per the 2025 OMA, TOS, ASN, and ACLM advisory) and add resistance training. The drug "not working" and the plan "not working" feel identical from the scale, and only body-composition data tells them apart.

Where Myo fits

The question "is my GLP-1 working?" is really four questions: Is my appetite down? Is my weight trending down? Am I losing fat and not muscle? And is my plan supporting it? Myo answers all four in one place, by putting your appetite and food-noise check-ins, your weight trend, and your fat-versus-muscle body-composition trend in a single view.

That means you judge progress on the metrics that count, not on how rough the side effects feel. Body-composition tracking and the muscle-loss trend flag are part of Myo Premium, while weight logging, check-ins, and the protein ring are free. When your appetite is quiet, your weight trend is down, and your muscle is holding, you have your answer, with data behind it.

References

• "Food noise" and GLP-1 modulation of brain reward circuits: PMC12770913.
• Weight-loss magnitude and timeline (semaglutide ~15% over 68 weeks): STEP 1, NEJM 2021 (Wilding et al.).
• Weight-loss magnitude (tirzepatide ~16 to 22.5%): SURMOUNT-1, NEJM 2022 (Jastreboff et al.).
• GLP-1 pharmacokinetics and steady state (semaglutide ~7-day half-life, ~4 to 5 weeks to steady state): PNAS 10.1073/pnas.2415815121.
• Lean-mass share of weight lost (~25 to 40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.
• Protein target during weight loss (~1.2 to 1.6 g/kg/day): 2025 joint advisory from OMA, TOS, ASN, and ACLM (PMC12264624).